B+
Bull case
25%
Probability
Target price
$6.00
Analysis reference price unavailable
Analysis 2026-05-14 · RankAlpha Sentiment Codex
AGEN
AgenusFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The best post-print bull read is that Q1 moved BOT+BAL from setup toward execution: early-access revenue reached $4.6 million, BATTMAN enrollment started in April, and the Zydus deal added capital plus manufacturing support, while the SEC investigation ended with no enforcement recommendation [#8-K-2026-05-11] [#10-Q-2026-05-11].
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.0.
What can break
Clinical and regulatory execution risk remains high because the thesis still depends on BATTMAN enrollment, data-package completion, and planned U.S./E.U. submission pathways [#8-K-2026-05-11] [#10-Q-2026-05-11].
Momentum
77
Value
52
Sentiment
6
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $3.00 · Bull $6.00 · Bear $1.50Analysis 2026-05-14; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-26 • Vendor: Data Vendor v1
Scores
As of 2026-10-26 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-14 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-26
Investment thesis
As of 2026-10-26
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-26. Definitions
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $24.50
Why
Momentum77 · Δ7d -15.8
Value52 · Δ7d -0.0
Sentiment6 · Δ7d -2.1
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Value remains the lead driver in the composite, 7D delta -0.0.
Contradictions & invalidation
- • Clinical and regulatory execution risk remains high because the thesis still depends on BATTMAN enrollment, data-package completion, and planned U.S./E.U. submission pathways [#8-K-2026-05-11] [#10-Q-2026-05-11].
- • Debt maturities remain meaningful, with $5.1 million due in June 2026 and $24.75 million due in November 2026, increasing refinancing and dilution risk [#10-Q-2026-05-11].
- • The bear read remains stronger in the near term because the company still carries going-concern language, needs additional capital to reach profitability, has near-dated debt maturities, and is relying on collections, financing, and trial execution to keep the plan intact.
Catalyst clock
2026-05-31
ASCO 2026 melanoma Phase 2 presentation
Lead driver: Value · See fundamentals
Momentum
77
8% active weight
Current posture
7d trendSoftening
Δ7d
-15.8
Δ21d
-14.7
Value
52
47% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.3
Sentiment
6
45% active weight
Current posture
7d trendSoftening
Δ7d
-2.1
Δ21d
+4.3
Why this grade
Composite grade F. Momentum 77.4 / Value 51.6 / Sentiment 5.9
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-05-14. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$3.00
Analysis reference price unavailable
Analysis 2026-05-14 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$1.50
Analysis reference price unavailable
Analysis 2026-05-14 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-26
Fundamentals (TTM)
As of 2026-10-26
Market Cap
$278.2M
Beta
1.62
Shares Out
45.16M
P/E (TTM) · Derived
-1811.8
P/S (TTM)
1.03
P/FCF (TTM) · Derived
-2.36
Rev YoY
+34.4%
EPS YoY
-98.5%
Gross Margin
+96.0%
Op Margin
+27.0%
Net Debt
$331.9M
Current Ratio
0.34
As of 2026-10-26 • Updated nightlySource: Internal modelMethods & Data